Krystal Biotech (KRYS) revenue and earnings history
Krystal Biotech reported revenue of $389M for fiscal 2025 (year ended Dec 31, 2025), +33.9% on the year before, and net income of $205M.
Revenue and net income, 10 fiscal years
Annual figures, newest first
| Fiscal year | Revenue | Operating income | Net income | Operating cash flow | Capital expenditure | Free cash flow | Stock-based pay | Share buybacks | Dividends paid | Cash at year end | Total debt at year end | Report |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025ended Dec 31, 2025 | $389M+33.9% | $161M | $205M | $201M | $12M | $189M | $54.5M | — | — | $496M | — | 10-K |
| 2024ended Dec 31, 2024 |
The latest quarter, insider trades and fund moves: Krystal Biotech (KRYS) on OQRO.
Common questions
What was Krystal Biotech's revenue in fiscal 2025?
$389M for the year ended Dec 31, 2025, as reported in its 10-K filed Feb 17, 2026. That is +33.9% on fiscal 2024 ($291M).
Has Krystal Biotech been profitable?
It reported a net loss in 7 of the years shown (2016, 2017, 2018, 2019, 2020, 2021, 2022). The highest net income was $205M in fiscal 2025.
What was Krystal Biotech's free cash flow in fiscal 2025?
$189M: operating cash flow of $201M minus capital expenditure of $12M. OQRO calculates free cash flow this way from the two filed lines.
Where these figures come from
The SEC’s companyfacts data: every figure Krystal Biotech tagged in XBRL in its annual and quarterly reports since 2009 (some reports carry a few earlier years as comparatives). For each fiscal year OQRO keeps the twelve-month totals from the annual report and the cash and debt at year end, and when a later report restates a year, the later figure. Read again whenever the company files.
Figures are as reported, in US dollars, with no adjustment for acquisitions, disposals or one-off items. Earnings per share are left out because a stock split changes them between reports. This page describes the past and is not investment advice. No language model wrote it.
